- GlobeNewswire•11 days agoAuven Therapeutics Announces Closing of Sale of Ocular Technologies Sarl, Holding Entity for Seciera™ for Treatment of Dry Eye Disease
Virgin Islands; LAUSANNE, Switzerland; FT. LAUDERDALE, Fla.; and HAMILTON, Bermuda, Jan. 06, 2017-- Auven Therapeutics, an international private equity company focused on the accelerated development of ...
- Barrons.com•29 days ago
Sun Pharmaceuticals' shares are under pressure after the U.S. Department of Justice last week filed the first charges in its generic drug antitrust investigation, accusing two former senior executives from Heritage Pharmaceutical of price fixing. Sun Pharmaceutical (524715.India) was among 14 drug makers to receive a letter in October from U.S. lawmakers as part of an investigation into the staggering price hikes for generic drugs. The DoJ risk cannot be ignored, according to Credit Suisse's Anubhav Aggarwal, who downgraded the Indian generic drug maker to Neutral with a new price target of 620 rupees.
- Bloomberg•last month
U.S. Food and Drug Administration inspectors in a recent visit to Sun Pharmaceutical Industries Ltd.’s plant in Halol, India, found that some testing programs weren’t adequately designed, and that failing ...
SUNPHARMA.NS : Summary for SUN PHARMACEUTICAL INR1(DEMAT) - Yahoo Finance
Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)
NSE - NSE Delayed Price. Currency in INR
Add to watchlist
|Day's Range||644.45 - 652.70|
|52 Week Range||571.90 - 898.45|
|PE Ratio (TTM)||21.18|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|